NR574 PSYCHOPHARMACOLOGY
(Substance Use) UPDATED ACTUAL
Questions and CORRECT Answers
METHADONE FLASHCARD (p. X, Stahl)
1. Class
2. MOA
3. Indications
4. Side effects (3)
5. Doses
6. Route
7. Pharmacokinetics (*metabolized by) - CORRECT ANSWER - 1. Class: mu opioid
receptor agonist
2. MOA: binds to mu opioid receptor
3. Indications: opioid use disorder
4. Side effects:
a. Respiratory depression
b. QTc prolongation (especially at higher doses > 100 mg)
c. Death (overdose effects)
5. Dose: 30-130 mg/day
6. Route: PO
7. Pharmacokinetics:
, *Metabolized by: 3A4
BUPRENORPHINE FLASHCARD (p. 111, Stahl)
1. Class
2. MOA
3. Indications
4. Side effects (2)
5. Doses
6. Routes (3)
7. Pharmacokinetics (*metabolized by) - CORRECT ANSWER - 1. Class: mu opioid
receptor partial agonist
2. MOA: binds to mu opioid receptor
3. Indications: *opioid use disorder*
4. Side effects (if used with other CNS depressants):
a. Respiratory depression
b. Death (overdose effects)
5. Dose: 8-32 mg/day
6. Routes:
a. *Sublingual* (good bioavailability)
b. Implant
c. Injection
7. Pharmacokinetics:
(Substance Use) UPDATED ACTUAL
Questions and CORRECT Answers
METHADONE FLASHCARD (p. X, Stahl)
1. Class
2. MOA
3. Indications
4. Side effects (3)
5. Doses
6. Route
7. Pharmacokinetics (*metabolized by) - CORRECT ANSWER - 1. Class: mu opioid
receptor agonist
2. MOA: binds to mu opioid receptor
3. Indications: opioid use disorder
4. Side effects:
a. Respiratory depression
b. QTc prolongation (especially at higher doses > 100 mg)
c. Death (overdose effects)
5. Dose: 30-130 mg/day
6. Route: PO
7. Pharmacokinetics:
, *Metabolized by: 3A4
BUPRENORPHINE FLASHCARD (p. 111, Stahl)
1. Class
2. MOA
3. Indications
4. Side effects (2)
5. Doses
6. Routes (3)
7. Pharmacokinetics (*metabolized by) - CORRECT ANSWER - 1. Class: mu opioid
receptor partial agonist
2. MOA: binds to mu opioid receptor
3. Indications: *opioid use disorder*
4. Side effects (if used with other CNS depressants):
a. Respiratory depression
b. Death (overdose effects)
5. Dose: 8-32 mg/day
6. Routes:
a. *Sublingual* (good bioavailability)
b. Implant
c. Injection
7. Pharmacokinetics: